B) Program on hospital-acquired infections
1. To reduce the incidence and to imporve the prognosis of hospital-acquired bacteremia.
Line 1. To reduce the incidence of catheter-related bacteremia in patients in conventional hospitalization and improvement of the prognosis.
Action 1
Design, application and evaluation of a set of preventive mesaures.
Responsible: Hospital Universitario Vall d´Hebron. Dr. Benito Almirante.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 2
Intervention for the improvement of the management and prognosis of the bacteremia for Staphylococcus aureus.
Responsible: Hospital Universitario Virgen Macarena. Dr. Jesús Rodríguez Baño.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 3
Document of consensus on the diagnosis, the prevention and the treatment of the CRB.
Responsible: Hosital Universitario Vall d´Hebrón. Dr. Benito Almirante.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 2. Improvement of the prognosis of hospital-acquired bacteremia.
Action 1
Integral Program on bacteremia..
Responsible: Hospital Universitario Virgen del Rocío. Dr. José Molina.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 2
Clinical epidemiology and prognosis of the bacteremia of meticiline reistant S. aureus (SAMR) - Impact of the treatment with daptomycin in strains with CMI of vancomicin > 1 mg/L. Prospective observacional study.
Responsible: Hospital Universitario Virgen Macarena, Hospital Universitario Bellvitge, Hospital Clinic,
Hospital Universitario Virgen Rocío. Dr. Fernando Docobo.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
2. To improve the prognosis of hospitalacquired pneumonia (HAP).
Line 1. Antimicobials treatment experimental models.
Action 1
Evaluation of new therapeutic options with commercialized and in process drugs.
Responsible: Hospital Universitario Virgen Rocío. Dr. José Miguel Cisneros. This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Líne 2. Therapeutic clinical trials.
Action 1
Optimisation of treatment with off-patent antimicrobial agents of ventilator-associated pneumonia (VAP) caused by Acinetobacter baumannii, Pseudomonas aeruginosa and other multidrug-resistant gramnegative bacili (MDRGNB)..
Responsible: Hospital Universitario Virgen Rocío. Dr. José Miguel Cisneros.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
3. To reduce the incidence and better the prognosis of the surgical site infection (SSI).
Line 1. To reduce the incidence of the surgical site infection (SSI).
Action 1
Impact of the detection of S. aureus holders and intervention strategies for reducing the incidence of postsurgical infections in specific high risk interventions (cardiac surgery, orthopedic surgery).
Responsible: Hospital Universitario Vall d´Hebron. Dr. Benito Almirante.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 2
Development and implementataion of a set of general mesaures to prevent surgical wound infection in colorectal, cardiac and prosthetics and orthopedic.
Responsible: Hospital Universtiario Bellvitge
Action 3
Optimization of the antimicrobial prphylaxis integrated int the PROA
Responsible: Hospital Universitario Virgen Rocío. Dr. José Miguel Cisneros.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 4
Consensus document on prevention of the SSI
Responsible: Hospital Univesitario Bellvitge
Line 2. To better the prognosis of SSI.
Action 1
Use of new therapeutic options.
Responsible: Hospital Universitario Bellvitge
Action 2
Development of Consensus documents on the clinical management of the SSI in prosthetics and orthopedic surgery.
Responsible: Hospital Universitario Bellvitge
4. To know the actual epidemiology on our environment, to evaluate the efficacy of new diagnostic tests and to better the prognosis on the invasive candidiasis.
Line 1. To describe the clinical epidemiology and the profile of antifungal resistance in patients with candidemia.
Action 1
Project on "Prospective population study on candidemia in Spain".
Responsible: Centro Nacional Microbiología -Micología-
Line 2. To better, evaluate and optimize the microbiologic diagnosis on invasive infections by Candida spp.
Action 1
Evaluation of the detection of fungal components and other indirect methods such as candidemia early diagnostics thechniques, including the quantification of beta-glucan, different antibodies and quantitative PCR bases techniques.
Responsible: Centro Nacional Microbiología -Micología-
Action 2
Development of multiple detection methods based in bioinformatics preceedings of phenotype and genotype characteristics of Candida spp.
Responsible: Centro Nacional Microbiología -Micología-
Line 3. To better the prognosis of invasive candidiasis.
Action 1
Update of the consensus document on clinical management of the invasive candidiasis.
Responsible: Centro Nacional Microbiología -Micología-
